GREAT BASIN SCIENTIFIC, INC. (NASDAQ:GBSN) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

GREAT BASIN SCIENTIFIC, INC. (NASDAQ:GBSN) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01

Story continues below

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 16, 2017, Great Basin Scientific, Inc. (the “Company”) disclosed in its Current Report on Form 8-K that the Company was not able to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 (“Form 10-Q”) which was due on August 14, 2017.On September 28, 2017, the Company disclosed in its Current Report on Form 8-K that the Company will not be able to file its Form 10-Q by the September 28, 2017 deadline to remain eligible for trading on the OTCQB market. On September 29, 2017, the Company received notice from the OTC Markets Group that due to the Company’s ongoing delinquency in the filing of its Form 10-Q, the Company will be moved from the OTCQB market to OTC Pink market before market opens on Monday, October 2, 2017.


About GREAT BASIN SCIENTIFIC, INC. (NASDAQ:GBSN)

Great Basin Scientific, Inc. is a molecular diagnostic testing company. The Company is focused on the development and commercialization of its molecular diagnostic platform designed to test for infectious diseases, especially hospital-acquired infections. Its commercially available tests are clostridium difficile (C. diff) and Group B Strep. Its system includes an analyzer and a diagnostic cartridge. Each analyzer contains a module into, which individual test cartridges are placed. Its other diagnostic assays in the late stages of product development include a pre-surgical nasal screen for Staphylococcus aureus (SA), food borne pathogen panel, panel for candida blood infections, test for pertussis and a test for Chlamydia tracomatis (CT)/Neisseria gonorrhea (NG). The Company also has a pipeline of assays in an early stage of development, including respiratory testing and sepsis (blood infection) panels. It markets a platform of molecular testing in small to medium sized hospitals.

An ad to help with our costs